REGENERON PHARMACEUTICALS, INC. Net Income Loss

Quick Answer

REGENERON PHARMACEUTICALS, INC. reported Net Income Loss of $4.50 billion for the year ending 2025.

  • REGENERON PHARMACEUTICALS, INC. showed an increase of +2.1% in Net Income Loss from 2024 to 2025.
  • This data is from REGENERON PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 4, 2026.
  • XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q1 2016: $181.39 million | Q2 2016: $196.22 million | Q3 2016: $264.80 million | Q4 2016: $253.12 million | Q1 2017: $248.90 million | Q2 2017: $387.70 million | Q3 2017: $388.30 million | Q4 2017: $173.50 million | Q1 2018: $478.00 million | Q2 2018: $551.40 million | Q3 2018: $594.70 million | Q4 2018: $820.40 million | Q1 2019: $461.10 million | Q2 2019: $193.10 million | Q3 2019: $669.60 million | Q4 2019: $792.00 million | Q1 2020: $624.60 million | Q2 2020: $897.30 million | Q3 2020: $842.10 million | Q4 2020: $1.15 billion | Q1 2021: $1.12 billion | Q2 2021: $3.10 billion | Q3 2021: $1.63 billion | Q1 2022: $973.50 million | Q2 2022: $852.10 million | Q3 2022: $1.32 billion | Q1 2023: $817.80 million | Q2 2023: $968.40 million | Q3 2023: $1.01 billion | Q1 2024: $722.00 million | Q2 2024: $1.43 billion | Q3 2024: $1.34 billion | Q1 2025: $808.70 million | Q2 2025: $1.39 billion | Q3 2025: $1.46 billion.
  • Over the full 18 years of available data (2008 to 2025), REGENERON PHARMACEUTICALS, INC.'s Net Income Loss has grown by 5,793.1%.
  • Historical annual values: Fiscal year 2025: $4.50 billion | Fiscal year 2024: $4.41 billion | Fiscal year 2023: $3.95 billion | Fiscal year 2022: $4.34 billion | Fiscal year 2021: $8.08 billion | Fiscal year 2020: $3.51 billion | Fiscal year 2019: $2.12 billion | Fiscal year 2018: $2.44 billion | Fiscal year 2017: $1.20 billion | Fiscal year 2016: $895.50 million | Fiscal year 2015: $636.06 million | Fiscal year 2014: $338.13 million | Fiscal year 2013: $413.74 million | Fiscal year 2012: $750.27 million | Fiscal year 2011: -$221.76 million | Fiscal year 2010: -$104.47 million | Fiscal year 2009: -$67.83 million | Fiscal year 2008: -$79.13 million.
  • Data sourced from SEC EDGAR public filings as of August 7, 2026.

Last verified: